SUPPLEMENTARY TABLE 1. MIC of different antibiotics (µg/ml) and QS inhibitors (µM) for planktonically grown cells. *MIC of the antibiotic when used in combination with BH (100 µM), CA (250 µM) or HAM (250 µM). ND: not determined.

MIC value for the different compounds alone or in combination
B. multivorans / B. cenocepacia / P. aeruginosa / S. aureus
Compounds / LMG13010 / LMG17588 / LMG18822 / LMG16656 / LMG16659 / LMG18828 / PAO1 / ATCC9027 / Mu50 / CS1
BH / > 125 / > 125 / > 250 / > 500 / > 500 / > 500 / > 500 / > 500 / ND / ND
CA / > 500 / > 500 / > 500 / > 500 / > 500 / > 500 / > 500 / > 500 / ND / ND
TOB / 64 / 64 / 128 / 256 / 512 / 256 / 2 / 1 / ND / ND
TOB-BH* / 64 / 64 / 128 / 256 / 512 / 256 / 2 / 1 / ND / ND
TOB-CA* / 64 / 64 / 128 / 256 / 512 / 256 / 2 / 1 / ND / ND
HAM / ND / ND / ND / ND / ND / ND / ND / ND / > 2000 / > 2000
VAN / ND / ND / ND / ND / ND / ND / ND / ND / 8 / 1
VAN-HAM* / ND / ND / ND / ND / ND / ND / ND / ND / 4 / 1
CLI / ND / ND / ND / ND / ND / ND / ND / ND / 512 / 0.256
CLI-HAM* / ND / ND / ND / ND / ND / ND / ND / ND / 256 / 0.128

SUPPLEMENTARY TABLE 2. Decrease in log CFU/biofilm when biofilms were treated with BH (100 µM), CA (250 µM) or HAM (250 µM). ND: not determined.

Strain / Treatment / Decrease in Log CFU/biofilm compared to an untreated CTRL obtained in the different model systems
MH / SCFMM / LCWPB / CWB / RHE
B. multivorans LMG13010 / BH / 0.31  0.11 / 0.10  0.54 / ND / ND / ND
CA / 0.21  0.05 / -0.02  0.34 / ND / ND / ND
B. multivorans LMG17588 / BH / 0.21  0.02 / 0.32  0.09 / ND / ND / ND
CA / 0.27  0.10 / 0.22  0.06 / ND / ND / ND
B. multivorans LMG18822 / BH / 0.26  0.03 / 0.19  0.19 / ND / ND / ND
CA / 0.07  0.31 / 0.10  0.04 / ND / ND / ND
B. cenocepacia LMG16656 / BH / 0.18  0.27 / 0.94  0.19 / ND / ND / ND
CA / 0.13  0.09 / 0.50  0.32 / ND / ND / ND
B. cenocepacia LMG16659 / BH / 0.22  0.10 / 0.30  0.12 / ND / ND / ND
CA / 0.20  0.12 / 0.31  0.11 / ND / ND / ND
B. cenocepacia LMG18828 / BH / 0.33  0.14 / 0.31  0.10 / ND / ND / ND
CA / 0.08  0.02 / 0.15  0.08 / ND / ND / ND
P. aeruginosa PAO1 / BH / 0.17  0.05 / 0.04  0.10 / 0.08  0.12 / 0.07  0.13 / ND
CA / 0.10  0.13 / 0.14  0.12 / 0.12  0.05 / 0.12  0.07 / ND
P. aeruginosa ATCC 9027 / BH / 0.11  0.10 / 0.15  0.09 / 0.10  0.16 / 0.12  0.12 / ND
CA / 0.01  0.20 / 0.21  0.10 / 0.05  0.12 / 0.03  0.11 / ND
S. aureus CS1 / HAM / 0.23  0.09 / 0.35  0.36 / 0.10  0.16 / 0.06  0.13 / 0.28  0.47
S. aureus Mu50 / HAM / 0.16 0.05 / 0.33  0.22 / 0.06  0.17 / 0.01  0.06 / 0.17  0.14

SUPPLEMENTARY TABLE 3: Percentage decrease in the number of CFU per biofilm (average  SD) when 24 h old P. aeruginosa WT and mutant biofilms grown in different model systems were treated with TOB or a combination of TOB and BH or CA. * results of combined treatment is significantly different from that of antibiotic treatment alone (p < 0.05). MH: Mueller-Hinton; SCFMM: synthetic cystic fibrosis medium with mucin.

Strain / Treatment / % decrease in CFU obtained in different model systems
MH / SCFMM
P. aeruginosa MH340 (WT) / TOB / 42.1  5.4 / 35.3  6.9
TOB-BH / 86.5  6.9* / 85.5  6.4*
TOB-CA / 92.3  5.6* / 91.1  9.2*
P. aeruginosa MH710 (ΔrhlIΔlasI) / TOB / 97.4  1.4 / 98.6  1.3
TOB-BH / 96.9  1.1 / 97.9  2.5
TOB-CA / 95.8  1.4 / 98.4  1.5